Press "Enter" to skip to content

Canada’s BC will be first province to switch patients to biosimilars

The Canadian province of British Columbia said on Monday that its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars, saving an estimated C$96.6 million ($71.9 million)over three years.

Original source: